AbbVie files NDA with US FDA for Parkinson's disease therapy

AbbVie has filed an NDA with the US FDA for ABBV-951 to treat motor fluctuations in individuals with advanced Parkinson’s disease (PD).

Related Keywords

Australia ,Illinois ,United States ,North Chicago ,Thomas Hudson ,Abbvie ,Abbvie Inc ,Drug Administration ,New Drug Application ,Pharmaceutical Powders ,Peptide Synthesis ,Protected Amino Acids ,Unnatural Amino Acids ,Handling Products ,Turnkey Process Systems ,